Federal Restricted Drug Programs
Federal restricted drug programs and related medication-processing requirements, such as pseudoephedrine and Risk Evaluation and Mitigation Strategies (REMS).
Federal Restricted Drug Programs is worth 3.2% of the PTCE inside the Federal Requirements domain (18.75% overall). It tests the special federal controls that sit on top of ordinary dispensing — the Combat Methamphetamine Epidemic Act (CMEA) for pseudoephedrine, and Risk Evaluation and Mitigation Strategies (REMS) for high-risk drugs. The principle: certain products carry enough abuse or safety risk that Congress or the FDA imposes extra steps — logging, ID checks, quantity caps, prescriber/pharmacy certification, or patient enrollment — before a dispense is legal.
CMEA and Pseudoephedrine Sales Limits
The Combat Methamphetamine Epidemic Act of 2005 (CMEA) regulates pseudoephedrine, ephedrine, and phenylpropanolamine as scheduled listed chemical products. Products must be kept behind the counter or in a locked case. Federal limits per purchaser: 3.6 grams per day, 9 grams per 30 days for in-store purchases, and 7.5 grams per 30 days by mail order. The buyer must present photo identification, and the sale is entered in a written or electronic logbook (name, address, product, quantity, date/time, and signature) retained for at least 2 years. Sellers must complete self-certification and employee training.
CMEA sets NO federal minimum purchase age for pseudoephedrine — an 18+ requirement is state law where it exists, not CMEA.
What REMS Is
A Risk Evaluation and Mitigation Strategy (REMS) is an FDA-required safety program (authorized by the 2007 FDA Amendments Act) for drugs whose serious risks require more than standard labeling to manage. REMS components can include a Medication Guide, a communication plan, a timetable for assessment, and — at the strictest level — Elements to Assure Safe Use (ETASU). ETASU can require prescriber certification, pharmacy or dispenser certification, patient enrollment in a registry, documentation of safe-use conditions, and monitoring or lab testing before each dispense.
ETASU is the most restrictive REMS tier — it can require certified prescribers, certified pharmacies, and enrolled patients.
Key REMS Programs
The iPLEDGE program for isotretinoin (for severe acne) prevents fetal exposure through mandatory prescriber, pharmacy, and patient enrollment, monthly pregnancy testing for those who can become pregnant, and confirmation before each fill. Thalidomide, lenalidomide (Revlimid), and pomalidomide (Pomalyst) carry REMS for embryo-fetal toxicity with restricted distribution. Transmucosal immediate-release fentanyl products are dispensed under the TIRF REMS Access program. Clozapine formerly required a REMS for severe neutropenia monitoring, but the FDA eliminated the Clozapine REMS in 2025 — as of that change, prescribers and pharmacies no longer enroll in the REMS or report ANC values through it, though neutropenia monitoring per the prescribing information still applies.
The Clozapine REMS was eliminated by the FDA in 2025 — do not describe it as an active REMS on current material.
Must-Know for the Exam
- ✓CMEA pseudoephedrine limits: 3.6 g/day, 9 g/30 days in-store, 7.5 g/30 days mail order
- ✓CMEA requires photo ID and a logbook retained at least 2 years
- ✓CMEA sets no federal minimum purchase age (any age limit is state law)
- ✓REMS is FDA-mandated; ETASU is its strictest tier
- ✓ETASU can require certified prescribers, certified pharmacies, and enrolled patients
- ✓iPLEDGE (isotretinoin) requires monthly pregnancy testing and full enrollment
- ✓Thalidomide, lenalidomide, and pomalidomide have REMS for embryo-fetal toxicity
- ✓The Clozapine REMS was eliminated by the FDA in 2025
Common Exam Mistakes
- ✗Stating that CMEA sets a federal minimum age (e.g., 18) to buy pseudoephedrine
- ✗Reversing the CMEA limits — mixing up the 9 g in-store cap with the 7.5 g mail-order cap
- ✗Retaining the pseudoephedrine logbook for less than the required 2 years
- ✗Describing the Clozapine REMS as still active
- ✗Confusing a Medication Guide (a basic REMS element) with full ETASU restrictions
Quiz yourself on Federal Restricted Drug Programs
Test what you just read — instant feedback on every question.
Start Federal Restricted Drug Programs Practice Quiz →Key Concepts — Part 1
1. Under the Combat Methamphetamine Epidemic Act (CMEA), what is the federal daily purchase limit for pseudoephedrine per customer?
3.6 grams
CMEA sets a federal daily purchase limit of 3.6 grams of pseudoephedrine per customer. 1.5 grams (A) is not the standard, 9 grams (C) is actually the 30-day limit, and D is incorrect because a daily limit does exist.
2. What is the federal 30-day purchase limit for pseudoephedrine products purchased in person under CMEA?
9 grams
CMEA sets the 30-day, in-person purchase limit at 9 grams. 3.6 grams (A) is the daily limit, 7.5 grams (B) is the 30-day limit specifically for mail-order or mobile vendor purchases, and 15 grams (D) exceeds the federal limit.
3. What is the federal 30-day purchase limit for pseudoephedrine when sold via mail order or mobile retail vendors under CMEA?
7.5 grams
CMEA sets a slightly lower 30-day limit of 7.5 grams for pseudoephedrine sold through mail order or mobile vendors, compared to 9 grams for in-person retail sales. A describes the in-person limit, C is the daily limit, and B is incorrect since a distinct mail-order limit exists.
4. What form of identification must a customer present to purchase a pseudoephedrine-containing product subject to CMEA?
A government-issued photo ID
CMEA requires customers to present valid government-issued photo identification before purchasing regulated pseudoephedrine products. A verbal statement (B), a credit card alone (C), or cash payment without ID (D) do not satisfy this requirement.
5. How long must pharmacies retain the logbook records of pseudoephedrine sales required under CMEA?
2 years
CMEA requires pseudoephedrine sales logbook records to be kept for a minimum of 2 years. 6 months (A) and 1 year (B) are too short, and 5 years (D) exceeds the federal minimum requirement.
6. What is the minimum age to purchase a pseudoephedrine-containing product regulated under CMEA?
There is no federal minimum age
CMEA itself does not set a federal minimum age to purchase regulated pseudoephedrine products — it requires photo ID, a logbook record, behind-the-counter/locked storage, and federal sales quantity limits (3.6g/day, 9g/30 days retail). Many states separately impose their own minimum purchase age (commonly 18), but that is state law, not a CMEA federal requirement.
7. Where must pseudoephedrine products regulated by CMEA be stored within a retail pharmacy?
Behind the counter or in a locked cabinet inaccessible to customers without staff assistance
CMEA requires these products to be kept behind the counter or in a locked cabinet so customers cannot access them without staff involvement, unlike ordinary OTC products on open shelving (A and C). Storing them in a pharmacist's personal office (D) is not a recognized or practical federal storage standard.
8. Which federal agency's authority primarily governs the CMEA restrictions on pseudoephedrine sales?
The Drug Enforcement Administration (DEA), since CMEA amended the Controlled Substances Act
CMEA amended the Controlled Substances Act, placing pseudoephedrine sales restrictions under DEA oversight as a scheduled listed chemical product, even though pseudoephedrine itself is not a scheduled controlled substance. FDA (A) governs drug approval generally but not this specific sales-tracking regime, and CMS (C) and EPA (B) are not the relevant agencies here.
9. What is a Risk Evaluation and Mitigation Strategy (REMS)?
An FDA-required strategy to manage known or potential serious risks associated with a drug, to help ensure its benefits outweigh its risks
REMS are FDA-mandated risk management programs required for certain drugs with serious safety concerns to help ensure benefits outweigh risks. They are not merely voluntary manufacturer marketing (A), unrelated to the FDA (C), or an insurance prior-authorization tool (D), though they may involve extra dispensing steps.
10. The iPLEDGE program is a REMS associated with which medication, due to its risk of severe birth defects?
Isotretinoin
iPLEDGE is the REMS program for isotretinoin, requiring registration, monthly pregnancy testing where applicable, and contraception verification due to severe teratogenic risk. Clozapine (A) was historically associated with its own REMS focused on neutropenia monitoring, but the FDA eliminated the clozapine REMS effective June 2025 — ANC monitoring is still clinically recommended per labeling, but is no longer a REMS requirement. Warfarin (B) and methotrexate (D) carry serious risks but are not managed under iPLEDGE or a REMS.
Key Concepts — Part 2
1. A REMS program requires the dispensing pharmacy to complete a Pharmacy Agreement Form and become specially certified before it may dispense the medication. This REMS requirement applies to which of the following?
Mifepristone
Mifepristone is subject to a REMS program that requires dispensing pharmacies to complete a Pharmacy Agreement Form and become certified with the REMS program before dispensing; prescribers must also be separately certified. Amoxicillin (B), metformin (C), and atorvastatin (D) are common medications with no REMS requirement.
2. What is meant by Elements to Assure Safe Use (ETASU) within a REMS program?
Specific, sometimes mandatory requirements such as prescriber or pharmacy certification, patient enrollment in a registry, or restricted distribution, designed to mitigate a drug's serious risks
ETASU are specific REMS requirements, such as certification, registries, or restricted distribution networks, that go beyond a standard Medication Guide to actively control access to higher-risk drugs. They are not merely optional pamphlets (A), a discount program (C), or a rule requiring physician-only dispensing (B), since pharmacies remain integral to dispensing these drugs.
3. Before dispensing a REMS-restricted medication with strict enrollment requirements, what should a pharmacy technician verify, under pharmacist supervision?
That the prescriber, pharmacy, and patient are properly enrolled or certified in the REMS program as required before dispensing
For REMS-restricted drugs with ETASU, technicians help verify that all required parties, such as the prescriber, pharmacy, and sometimes the patient, are properly enrolled or certified before the medication can be dispensed. Insurance type (A), prior fill history at another pharmacy (B), and cost comparison (D) are not the REMS compliance check required here.
4. Thalidomide, marketed as Thalomid, has a REMS program primarily because of which serious risk?
Risk of severe birth defects (teratogenicity) if taken during pregnancy
Thalidomide's REMS exists primarily because of its well-documented, severe teratogenic risk, historically causing significant birth defects. Liver toxicity (A), hearing loss (C), and universal severe allergic reaction (D) are not the primary risk driving thalidomide's REMS requirements.
5. What is a key component often required by REMS programs for extended-release and long-acting opioid analgesics?
Prescriber education and mandatory distribution of patient counseling materials, such as a Medication Guide
The opioid analgesic REMS emphasizes prescriber education and ensuring patients receive counseling materials like a Medication Guide about safe use and disposal. It does not mandate cash-only payment (A), hospital-only administration (C), or impose refill bans beyond what the drug's schedule already dictates (D).
6. Is pseudoephedrine itself classified as a federal controlled substance under the Controlled Substances Act (CSA)?
No, it is regulated federally as a scheduled listed chemical product under CMEA amendments to the CSA, distinct from the drug schedules I through V
Pseudoephedrine is not placed in Schedules I-V; instead, CMEA created a separate federal category, scheduled listed chemical products, subjecting it to sales, storage, and recordkeeping restrictions distinct from the CSA's drug schedules. A and B incorrectly assign it a drug schedule, and D ignores the substantial federal restrictions that do apply.
Ready to test your knowledge?
Practice questions with instant feedback and explanations.
Take a PTCB Practice Test →